Introduction: Treatment options for metastatic PCC/PGL and related hypertension (HTN) are limited. Experiences in PRRT suggest favourable disease control, but lack of data on HTN response.
Aim(s): We assessed PRRT outcomes in patients (pts) with high somatostatin receptor (SSTR) expression from 2 referral centres.
Materials and methods: 16 pts (M:F=11:5; 21-77y.o) treated with 177Lu-DOTA-octreotate were retrospectively reviewed. Median cumulative activity 21.5 GBq, most had 4 cycles, 7 had radiosensitising chemotherapy. 4 pts had SDHB mutation, 1 SDHD, 2 negative and 9 unknown. 12 pts were treated for secondary HTN and 4 pts for non-functional metastatic disease/recurrence.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Dr Grace Kong
To read results and conclusion, please login ...
Further abstracts you may be interested in